Hard Financial Statements From 2010 to 2025
Hard To's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Hard To's valuation are provided below:Hard to Treat does not presently have any fundamental trends for analysis.
Check Hard To financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hard To's main balance sheet or income statement drivers, such as , as well as many indicators such as . Hard financial statements analysis is a perfect complement when working with Hard To Valuation or Volatility modules.
Check out the analysis of Hard To Correlation against competitors. Hard to Treat Company Current Valuation Analysis
Hard To's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hard To Current Valuation | 254.37 K |
Most of Hard To's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hard to Treat is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Hard to Treat has a Current Valuation of 254.37 K. This is 100.0% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Hard to Treat Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hard To's current stock value. Our valuation model uses many indicators to compare Hard To value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hard To competition to find correlations between indicators driving Hard To's intrinsic value. More Info.Hard to Treat is one of the top stocks in profit margin category among its peers. It also is one of the top stocks in operating margin category among its peers reporting about 1.09 of Operating Margin per Profit Margin. Comparative valuation analysis is a catch-all technique that is used if you cannot value Hard To by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Hard To Financial Statements
Hard To shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Hard To investors may analyze each financial statement separately, they are all interrelated. The changes in Hard To's assets and liabilities, for example, are also reflected in the revenues and expenses on on Hard To's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China. Hard To operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hard Stock Analysis
When running Hard To's price analysis, check to measure Hard To's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hard To is operating at the current time. Most of Hard To's value examination focuses on studying past and present price action to predict the probability of Hard To's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hard To's price. Additionally, you may evaluate how the addition of Hard To to your portfolios can decrease your overall portfolio volatility.